GLPwatch
Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity.
Am J Cardiol · 2022
Last updated 2026-07-17| Journal | Am J Cardiol, 2022 |
|---|---|
| Citations | 6 |
| Relative citation ratio | 0.30 |
| NIH percentile | 18 |
| Molecules | semaglutide |
| Conditions studied | Obesity, Cardiovascular Risk Reduction |
Full record and abstract on PubMed 35599190 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.